BCHMF Stock Chart & Stats
$89.59
--
Market closed
$89.59
--
Day’s Range― - ―
52-Week Range$58.30 - $108.92
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$7.10B
Enterprise Value$5.05B
Total Cash (Recent Filing)$30.99M
Total Debt (Recent Filing)$57.39M
Price to Earnings (P/E)38.2
Beta1.26
Next Earnings
Jul 30, 2026EPS Estimate
0.51Next Dividend Ex-DateN/A
Dividend Yield1.45%
Share Statistics
EPS (TTM)1.99
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio1.27
Price to Book (P/B)3.08
Price to Sales (P/S)6.46
P/FCF Ratio-93.15
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue7.27
Enterprise Value/Gross Profit25.31
Enterprise Value/Ebitda28.11
Forecast
1Y Price Target
$107.15Price Target Upside19.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)2.91
Revenue Forecast (FY)$1.18B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and a growing equity base give Bachem durable financial flexibility. This reduces refinancing and solvency risk, supports capital spending for capacity and R&D, and enables the company to withstand cyclical demand swings in the CDMO market without overreliance on external funding.
Revenue Growth And ProfitabilitySteady revenue expansion through 2025 paired with a roughly 21% net margin indicates a resilient, profitable CDMO business model. Sustained top-line growth plus solid margins point to recurring commercial demand and operational scale that support long‑term earnings and reinvestment capacity.
Operating Cash GenerationPositive and improving operating cash flow in 2025 shows the core business generates cash even while FCF is negative. For a CDMO with recurring manufacturing contracts, sustained operating cash supports working capital needs and funds organic growth, helping underpin medium‑term financial stability.
Bears Say
Persistent Negative Free Cash FlowPersistent negative free cash flow across multiple years suggests heavy capex or rising working capital that absorbs cash. Over the medium term this can limit dividends, share buybacks, or internal investment unless cash conversion improves, potentially forcing external financing for growth.
Step-up In Debt In 2025A notable increase in total debt in 2025 marks a move away from prior near‑zero leverage. If operating cash conversion stays uneven, even modest additional debt could raise interest and refinancing exposure and slightly constrain financial flexibility for strategic investments.
Gradual Margin CompressionGradual drift in margins versus 2021–2022 indicates emerging pressure on profitability, possibly from mix shifts, pricing or cost increases. Sustained margin compression would reduce free cash generation and returns, requiring efficiency or pricing actions to restore historical profit levels.
Bachem Holding AG News
BCHMF FAQ
What was Bachem Holding AG Class B’s price range in the past 12 months?
Bachem Holding AG Class B lowest stock price was $58.30 and its highest was $108.92 in the past 12 months.
What is Bachem Holding AG Class B’s market cap?
Bachem Holding AG Class B’s market cap is $7.10B.
When is Bachem Holding AG Class B’s upcoming earnings report date?
Bachem Holding AG Class B’s upcoming earnings report date is Jul 30, 2026 which is in 27 days.
How were Bachem Holding AG Class B’s earnings last quarter?
Bachem Holding AG Class B released its earnings results on Mar 12, 2026. The company reported $1.644 earnings per share for the quarter, beating the consensus estimate of $1.149 by $0.494.
Is Bachem Holding AG Class B overvalued?
According to Wall Street analysts Bachem Holding AG Class B’s price is currently Undervalued.
Does Bachem Holding AG Class B pay dividends?
Bachem Holding AG Class B pays a Annually dividend of $0.575 which represents an annual dividend yield of 1.45%. See more information on Bachem Holding AG Class B dividends here
What is Bachem Holding AG Class B’s EPS estimate?
Bachem Holding AG Class B’s EPS estimate is 0.51.
How many shares outstanding does Bachem Holding AG Class B have?
Currently, no data Available
What happened to Bachem Holding AG Class B’s price movement after its last earnings report?
Bachem Holding AG Class B reported an EPS of $1.644 in its last earnings report, beating expectations of $1.149. Following the earnings report the stock price went up 8.803%.
Which hedge fund is a major shareholder of Bachem Holding AG Class B?
Currently, no hedge funds are holding shares in BCHMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bachem Holding AG Class B
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
BCHMF Stock 12 Month Forecast
Average Price Target
$107.15
▲(19.60% Upside)
Ownership Overview
―
Insiders
1.30% Mutual Funds
― Other Institutional Investors
96.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---